Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 4,445 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $7.45, for a total value of $33,115.25. Following the transaction, the executive vice president owned 129,799 shares of the company’s stock, valued at approximately $967,002.55. The trade was a 3.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vir Biotechnology Stock Up 5.4%

VIR stock opened at $10.00 on Thursday. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $10.94. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -3.16 and a beta of 1.69. The business’s fifty day simple moving average is $6.88 and its two-hundred day simple moving average is $6.02.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The firm had revenue of $64.07 million during the quarter, compared to analyst estimates of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The business’s revenue was up 417.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.76) earnings per share. Research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analysts Set New Price Targets

VIR has been the topic of a number of research analyst reports. Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price on the stock in a research note on Tuesday. Needham & Company LLC increased their price objective on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Evercore reaffirmed an “outperform” rating and set a $18.00 target price on shares of Vir Biotechnology in a research report on Tuesday. Finally, Barclays increased their price target on Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.88.

Institutional Trading of Vir Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in shares of Vir Biotechnology in the 2nd quarter valued at $35,000. FNY Investment Advisers LLC bought a new stake in Vir Biotechnology during the third quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Vir Biotechnology by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after purchasing an additional 1,390 shares in the last quarter. UMB Bank n.a. grew its stake in Vir Biotechnology by 1,418.7% in the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after purchasing an additional 6,597 shares during the last quarter. Finally, Federated Hermes Inc. raised its holdings in Vir Biotechnology by 153.8% in the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.